medtourism.guideIndependent check of what clinics publish

Cell and gene therapy and stem cells: rules by country

What the law or the regulator says about stem-cell, cell and gene therapies in 101 countries, each line with its official source.

Checked 15 Nov 2026Not advice
What this page covers. Rules and their official sources only, not whether a treatment works.
CountryRule and source
Albania
  • Law No. 10454 of 21 July 2011 governs transplantation of tissues, cells and organs. It prohibits transplantation of tissues, cells and organs for financial gain and genetic manipulation of embryos, including for transplantation. source
Antigua and Barbuda
  • The Stem Cell Research and Therapy Act, No. 11 of 2019, sets out a National Stem Cell Oversight Committee, licences for laboratories and research facilities and a register of licensed facilities. source
Argentina
  • ANMAT lists Disposición 179/2018 as the instrument setting requirements for advanced-therapy medicines. source
  • ANMAT Disposición 179/2018 sets production, marketing-authorisation, registration and surveillance rules for industrially produced gene therapy, somatic cell therapy, tissue-engineered and combination advanced therapy medicines. source
  • INCUCAI Resolution 28/2020 establishes a prior process for approval or renewal related to medical products containing cells or tissues of human origin before starting the covered ANMAT registration procedure. source
Armenia
  • A Ministry of Health order establishes requirements for processing, assessment, storage and transport of haematopoietic stem cells from peripheral blood, marrow and cord blood for transplantation. source
Australia
  • TGA guidance places autologous human cell and tissue products into fully regulated, exempt or excluded routes depending on the product and setting. The guidance describes a restricted hospital exclusion under practitioner supervision and different criteria for certain uses outside hospitals. source
  • TGA regulates cell and gene therapies under its biologicals or prescription medicines frameworks and identifies CAR-T as an example regulated under the biologicals framework. source
  • TGA warns that some stem cell treatments sold for therapeutic or cosmetic use may be unproven, illegal and harmful. source
  • TGA describes routes for approved access to biological products that are outside the Australian Register of Therapeutic Goods. These include eligible individual-patient access through the Special Access Scheme and Authorised Prescriber pathways as well as clinical trials. source
Austria
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
  • BASG guidance identifies an Austrian hospital exemption for qualifying advanced therapy medicinal products derived from human cells and tissues. source
Azerbaijan
  • Law No. 189-VIQ governs human organ and tissue donation and transplantation and specifically addresses bone marrow and stem cell donation by persons under 18 in Articles 18.2 and 18.3. source
Bahamas
  • The Longevity and Regenerative Therapies Act, No. 51 of 2024, covers stem cell, regenerative and gene therapies. It repeals the former Stem Cell Research and Therapy Act, subject to transitional provisions for approvals in good standing. source
  • Under the Longevity and Regenerative Therapies Act, the Ethics Committee may grant full, provisional or research approval. The Act requires a separate written commencement notice from the Board before administration or research can start. source
  • The Appointed Day Notice, S.I. No. 73 of 2024, specifies 1 September 2024 as the commencement of the Longevity and Regenerative Therapies Act. source
Bahrain
  • NHRA's published import restrictions list stem cells as restricted to NHRA-approved clinical research and orthopaedic procedures. source
  • Bahrain’s Cabinet reported the use of Casgevy to treat a patient with sickle cell disease. The Ministry of Health identifies it as a CRISPR-based treatment. source
Bangladesh
  • DGDA publishes Guidelines for Regulatory Approvals of Stem Cell and Cell Based Products. They cover the quality, non-clinical and clinical information for assessment of medicinal products made from stem cells. source
Barbados
  • Parliament’s official tracker records passage of the Human Tissue Transplant Act in both houses, with final House passage on 14 July 2026. source
Belarus
  • No official source found (checked 15 nov 2026).
Belgium
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Bosnia and Herzegovina
  • Federation-level law extends tissue transplantation provisions to cells including haematopoietic stem cells. Its transplantation provisions exclude private activity in the stated scope. source
Brazil
  • Anvisa applies RDC 505/2021 to registration of advanced therapy products and RDC 506/2021 to investigational advanced-therapy clinical research. source
  • Anvisa operates a narrow exception for non-routinely produced cell or tissue-engineered advanced therapies, for specific patients at imminent risk of death without a therapeutic alternative in Brazil, requiring prior communication. source
  • Anvisa requires prior authorisation for eligible gene therapy products that are produced non-routinely for specific patients at imminent risk of death without a therapeutic alternative in Brazil. source
  • Anvisa publicly warns about stem cell products marketed without approval and asks the public to report suspected use or sale. source
  • Anvisa publishes its list of registered advanced therapy products and associated approval conditions and documents. source
Bulgaria
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Cambodia
  • No official source found (checked 15 nov 2026).
Canada
  • Health Canada considers most autologous cell therapy products drugs subject to the Food and Drugs Act and its regulations. Its position paper identifies a narrow exception for certain autologous, minimally manipulated lymphohematopoietic cells intended for homologous use in transplantation. source
  • Health Canada warns that clinics have marketed unauthorised stem cell therapies with unproven claims and that treatment using the patient's own cells can still carry serious risks. source
  • Health Canada’s Drug Product Database includes Casgevy (exagamglogene autotemcel), an example of an authorised gene therapy product. source
Cayman Islands
  • The official 2026 Appraisal of Clinical Trial Applications guidelines give the Health Practice Commission a review role for clinical trial applications. source
China
  • State Council Order No. 818 requires approval by the national health authority before covered new biomedical technologies move from clinical research into clinical application. Qualified institutions may provide an approved application and charge fees in accordance with the rules. source
  • NMPA conditionally authorised marketing of the gene-modified autologous CAR-T product inaticabtagene autoleucel (纳基奥仑赛) in 2023, one example of the separate drug marketing-authorisation route. source
Colombia
  • Law 2253 of 14 July 2022 creates the official national public donor registry for haematopoietic progenitor cells and establishes a framework for associated activities. source
Costa Rica
  • The regulation on conventional adult stem cell and autologous platelet-rich plasma therapies permits qualifying public, private and mixed health facilities to provide covered procedures without an additional authorisation, subject to Ministry inspections. source
Croatia
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Cyprus
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Czech Republic
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Denmark
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Dominican Republic
  • Ministry Resolution 000018 of 9 November 2017 requires DIGEMAPS review for covered cellular therapies. Applications include qualifying evidence of safety and efficacy or an approved research protocol. Covered therapies must be prescribed and administered by a physician with a relevant specialty. source
Ecuador
  • The Ministry of Public Health states that the implementing regulation for the Organic Law on Donation and Transplantation of Organs, Tissues and Cells includes cell therapy and therapeutic transplantation activity. source
  • Executive Decree No. 1205 gives the National Institute for Donation and Transplantation of Organs, Tissues and Cells (INDOT) oversight functions for cellular or regenerative therapy within the scope of the transplantation regulation. source
Egypt
  • The Egyptian Drug Authority’s regulatory index publishes a 2026 guideline on registering biological products under Chairman’s Decree 343/2021. source
El Salvador
  • The Special Law on Transplants of Cells, Tissues and Human Organs permits living-donor sourcing of haematopoietic progenitor cells for autologous or allogeneic transplant with scientifically approved indications under Article 25. Article 42 prohibits therapeutic use of embryonic and fetal stem cells and other cells or tissues without scientifically established therapeutic indication. source
Estonia
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Finland
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
France
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Georgia
  • Article 44 of the Law on Medical Practice requires written informed consent for gene therapy. The consolidated version also specifies written consent for transplantation or use of human tissue or cells effective 1 September 2026. source
Germany
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
  • Paul-Ehrlich-Institut describes Germany’s national hospital-exemption authorisation under section 4b of the Medicinal Products Act (AMG). source
Greece
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Guatemala
  • Decree No. 5-2024 governs disposition and transplantation of human organs, tissues and cells. Congress lists 2 April 2024 as the effective date. source
Honduras
  • Article 1 of Decree No. 329-2013 applies the national transplantation law to cells or other anatomical material implanted by clinical or laboratory means for therapeutic, genetic or aesthetic purposes. source
Hong Kong
  • Advanced therapy products, including gene and somatic cell therapies, are pharmaceutical products under the Pharmacy and Poisons Ordinance (Cap. 138). The Drug Office explains pharmaceutical registration, manufacturing and supply controls and provides consumer guidance. source
  • The Drug Office publishes a register of advanced therapy products. source
  • The Pharmacy and Poisons Board publishes licence conditions for manufacture of an unregistered advanced therapy product for the treatment of a particular patient. Drug Office guidance also describes separate case-by-case import licensing for unregistered pharmaceutical products for particular patients. source
Hungary
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Iceland
  • EFTA records that Regulation (EC) No 1394/2007 on ATMPs was incorporated into the EEA Agreement. source
  • The Medicinal Products Act No. 100/2020 lists Regulation (EC) No 1394/2007 among the EEA instruments it implements. source
India
  • The 2017 national stem cell research guidelines treat clinical use of stem cells as investigational except approved indications for haematopoietic stem cell transplantation. source
  • The 2019 national gene therapy guidelines say candidate investigational products should only be used within approved clinical trials in the development phase. source
  • An April 2024 Government of India release documents the launch of NexCAR19, an example of a gene-modified cellular treatment introduced after the 2019 gene therapy development guidelines. source
Indonesia
  • The Ministry of Health states stem cell therapy must be administered by appropriately specialised physicians at licensed facilities. The cells must come from a processor licensed by the Ministry and/or BPOM. The Ministry describes a staged route from clinical research to nationally approved service standards. source
  • BPOM classifies cell and gene therapy products as prescription medicines. On 16 October 2026 BPOM said it had issued no marketing authorisations for therapeutic stem cell or tissue-engineered products or human-cell secretome or exosome products. It distinguished clinical-trial authorisation from authorisation for commercial sale. source
  • Health Ministry Regulation No. 32 of 2018 governs the provision of stem-cell and other cellular services. The Ministry’s legislative database publishes the legal text and metadata. source
Iran
  • A peer-reviewed Iranian guideline article describes the national ethical framework for research on stem cells and regenerative medicine. source
Ireland
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Israel
  • Ministry of Health Circular 6/09 describes regulatory and ethics approval for investigational gene therapy, including how investigational use for an individual patient is reviewed. source
  • The Ministry of Health provides a pharmaceutical product database for checking a marketed product’s registration and authorised uses. source
Italy
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Jamaica
  • No official source found (checked 15 nov 2026).
Japan
  • Under the Act on the Safety of Regenerative Medicine, providers must follow procedures for the applicable risk class and file a regenerative-medicine provision plan. MHLW states that providing covered care without filing a plan violates the Act. source
  • PMDA publishes regulatory materials for regenerative medical products under the Pharmaceuticals and Medical Devices Act, including guidance on conditional and time-limited approval. source
Jordan
  • The Ministry of Health publishes Stem Cell Regulation No. 10 of 2014 and related instructions. It includes licensing provisions for stem cell banks and restrictions on embryonic stem cell activities. source
Kazakhstan
  • A Ministry of Health order under Article 215 of the Health Code sets procedures for searching and activating haematopoietic stem cell donors. source
Kenya
  • The Ministry’s Policy on Human-Derived Medical Products includes stem cells in its framework for use and oversight of human-derived medical products. source
Latvia
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Lebanon
  • Law No. 240 of 22 October 2012 provides for therapeutic stem-cell culture techniques under conditions including performance at a university medical centre licensed by the Ministry of Public Health. source
Lithuania
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Malaysia
  • NPRA's second-edition guidance classifies higher-risk cell and gene therapy products as Class II biologics and describes product registration and clinical-trial authorisation processes. source
  • Drug Control Authority Directive 19/2020 states that only registered cell and gene therapy products may be marketed from 1 January 2021. The directive separately addresses implementation for established standard-of-care haematopoietic stem cell therapies. source
Maldives
  • No official source found (checked 15 nov 2026).
Malta
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Mauritius
  • The Human Tissue (Removal, Preservation and Transplant) Act 2018 applies only to donated tissue. The definition of tissue includes groups of cells and excludes specified embryonic, foetal and reproductive organs or structures. source
Mexico
  • Cofepris provides a sanitary licence for establishments that obtain, process, conserve or apply progenitor or stem cells, tissues or cells. source
  • In a public notice Cofepris stated it had not authorised any clinical protocol substantiating the stem-cell treatments it described. source
  • Cofepris has a public viewer for authorised medicines. Product authorisation for a gene therapy must be verified for the individual medicine. source
Moldova
  • Law No. 42-XVI of 6 March 2008 governs organ, tissue and human-cell transplantation. An implementing government decision establishes a Transplant Agency subordinate to the Ministry of Health. source
Montenegro
  • The Law on Procurement and Transplantation of Human Tissues and Cells for Treatment covers haematopoietic cells from peripheral blood, umbilical cord and marrow stem cells and adult stem cells, subject to any separate law. source
Morocco
  • The Ministry of Health states that collection, processing and autologous administration of cellular therapy preparations for treatment or research are restricted to approved public or private university hospital centres under its circular. The circular also requires informed consent. source
Nepal
  • The Nepal Health Research Council’s National Ethical Guidelines for Health Research include a section on stem cell research in humans. source
Netherlands
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
  • The Health and Youth Care Inspectorate (IGJ) must approve preparation and use of products under the hospital exemption. source
New Zealand
  • Medsafe states that Ministerial consent is required for sale, supply, distribution or promotion of medicines in New Zealand, subject to exemptions described in the Medicines Act 1981. source
  • Medsafe lists Zolgensma (onasemnogene abeparvovec) among medicines approved for paediatric patients with spinal muscular atrophy, a product-specific example of authorised clinical gene therapy. source
Nicaragua
  • Law No. 847 governs donation and transplantation of organs, tissues and cells for therapeutic, teaching and research purposes and also covers autologous transplantation subject to listed exclusions, including embryonic stem cells. source
North Macedonia
  • The Law on Removal and Transplantation of Parts of the Human Body for Treatment includes human cells and defines haematopoietic stem cells and allogeneic transplantation. source
Norway
  • EFTA records that Regulation (EC) No 1394/2007 on ATMPs was incorporated into the EEA Agreement. source
  • The Norwegian Medical Products Agency administers a hospital exemption for qualifying ATMP use and publishes application guidance. source
Oman
  • Sultan Qaboos University’s Department of Haematology identifies bone marrow transplantation as a clinical service. source
Pakistan
  • Minutes of DRAP's 298th Central Licensing Board meeting record the Authority’s 6 November 2019 decision to classify stem cells as biological products subject to biologicals requirements. source
Panama
  • Executive Decree No. 2 of 2013 establishes Panama’s guidelines for stem cell use. source
Peru
  • MINSA Resolution 520-2014 approves the national technical standard for haematopoietic progenitor cell transplantation. source
  • MINSA Resolution 435-2023 updates sections 6.2.1.1 and 6.2.1.2 of the national technical standard for haematopoietic progenitor cell transplantation. source
Philippines
  • Department of Health Administrative Order 2013-0012 sets rules for stem cell and cell-based or cellular therapies, including oversight of facilities and products. source
Poland
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Portugal
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Qatar
  • Ministry of Public Health health-research governance procedures include official review of gene therapy and stem cell clinical research proposals. source
Romania
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Russia
  • Roszdravnadzor publishes the scope of its regulatory responsibilities for biomedical cell products, including oversight of their circulation. source
  • Government Resolution No. 213 of 24 February 2025 governs biotechnological medicinal products specially prepared in the administering medical organisation for an individual patient’s prescription. source
Saudi Arabia
  • SFDA publishes a classification guide covering advanced therapy medicinal products, including those based on cells or genes. source
  • SFDA lists Casgevy as a registered product, an example of a gene-editing therapy with marketing authorisation. source
Serbia
  • The Law on Human Cells and Tissues covers haematopoietic stem cells from peripheral blood, umbilical cord blood and bone marrow. It provides for a national registry of haematopoietic stem cell donors at the Serbian Blood Transfusion Institute. source
  • Serbia’s Law on Medicines and Medical Devices classifies gene therapy and somatic cell therapy products among medicinal products for advanced therapy. source
Singapore
  • HSA requires written acknowledgment of notification before supply of Class 1 cell, tissue and gene therapy products. The lower-risk classification includes specified minimally manipulated human cells or tissues for homologous use and applies only when all conditions are met. source
  • Class 2 cell, tissue and gene therapy products, including products such as gene-modified cells and therapeutic gene vectors, are subject to HSA product registration before standard supply. source
  • HSA's e-services provide public cell, tissue and gene therapy product information and regulatory application links. source
Slovakia
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Slovenia
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
South Africa
  • The National Health Act’s Regulations Relating to Stem Cell Banks specify conditions for the release of stem cell products by banks for therapeutic use and rules on use of stem cells and their products. source
  • SAHPRA’s guideline on amendments to biological medicines includes products developed for human gene therapy within its scope. source
South Korea
  • The Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biopharmaceuticals covers cell and gene therapies. Article 12-2 requires committee assessment of a treatment plan for treatment in a regenerative-medicine institution and limits provision under a favourable determination to up to five years before reassessment. source
  • The Act also provides an item-specific marketing approval channel for advanced biopharmaceuticals through the Ministry of Food and Drug Safety. source
Spain
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
  • The Spanish medicines agency AEMPS authorises non-industrially manufactured advanced therapies under Royal Decree 477/2014 as a hospital exemption. source
Sri Lanka
  • Cabinet approved the National Policy on Organs, Tissues and Cell Transplantation, stating the aim of safeguarding donor and recipient rights. source
Sweden
  • Cell and gene therapies that qualify as advanced therapy medicinal products (ATMPs) follow the EU centralised marketing-authorisation route. source
  • Non-routinely prepared custom ATMPs may be used for an individual prescription in a hospital in the same member state under a physician’s exclusive professional responsibility. The national competent authority must authorise manufacture. source
  • EMA and HMA warn that unregulated cell, tissue and gene treatments can cause serious harm. Their warning identifies unregulated dendritic cell products marketed as cancer treatments and advises checking regulatory status for the intended indication. source
Switzerland
  • Swissmedic treats somatic-cell and tissue-engineered transplant products, gene therapies and certain other nucleic-acid products as advanced therapy medicinal products, under the relevant Swiss therapeutics or transplantation legislation. source
  • Swissmedic cautions that treatments based on human tissue and cells, including aesthetic offerings, are subject to therapeutic-product and transplantation restrictions. source
Taiwan
  • The Regenerative Medicine Act took effect on 1 January 2026. Article 12 requires central approval and local registration before a medical institution uses regenerative techniques or designated regenerative products. The Ministry's portal publishes searchable information. source
  • The Regenerative Medicinal Products Act establishes the approval framework for regenerative medicinal products, including a conditional approval mechanism. source
Thailand
  • Thai FDA describes a dedicated regulatory pathway for advanced therapies including cellular and gene-based products, with a focus on manufacturing oversight and clinical evidence for registration or commercial supply. source
Tunisia
  • No official source found (checked 15 nov 2026).
Turkey
  • TİTCK issues licensing guidance for facilities that handle human tissues, cells and derived products. source
  • Article 6 of Turkey’s 2023 Advanced Therapy Medicinal Products Licensing Regulation bars marketing covered products without authorisation from TİTCK. source
Ukraine
  • The State Expert Centre of the Ministry of Health publishes in-force clinical guidelines for haematopoietic stem cell transplantation in adults and children. source
United Arab Emirates
  • Dubai Health Authority’s stem cell services standards generally restrict licensed routine practice in DHA-licensed facilities to minimally manipulated autologous cells. DHA authorisation is needed for exceptions identified in its standards. source
  • Abu Dhabi’s Department of Health announced the introduction of Casgevy at the Abu Dhabi Stem Cells Center as a gene-editing treatment for eligible patients with sickle cell disease or transfusion-dependent beta-thalassaemia. source
  • DHA bars facilities within its licensing scope from promoting or administering unapproved or unproven stem cell therapies and requires cooperation in monitoring and reporting unregulated practices. source
United Kingdom
  • MHRA authorises marketing of advanced therapy medicinal products in the United Kingdom. MHRA also describes hospital exemption and specials routes for certain unlicensed ATMPs, each requiring the relevant manufacturer’s licence. source
  • Regulation 171 of the Human Medicines Regulations 2012 provides a hospital exemption subject to conditions for qualifying ATMPs used in a UK hospital. source
United States
  • FDA publishes a list of approved cellular and gene therapy products. Product authorisation is specific to its labelled use. source
  • FDA warns that unapproved regenerative medicine products, including marketed stem cell and exosome therapies, may cause serious harm and generally require FDA oversight in a clinical trial before approval. source
Uruguay
  • Article 329 of Law No. 18.362 places regenerative medicine and the donation and transplantation of human cells, tissues and organs within the remit of the National Institute of Donation and Transplantation. source
Uzbekistan
  • Presidential Resolution PP-4592 includes autologous stem cell transplantation for people with myeloma or lymphoma within the specialist haematology service development programme. source
Vietnam
  • Circular 23/2024/TT-BYT establishes the Ministry’s list of medical examination and treatment techniques. Stem-cell procedures appear in the technical annexes. Appendix 2 took effect on 1 July 2026. source

Special regimes